RxDoctor Payments Data

Eric Richter, MD

Urology · Pueblo, CONPI 1013117092

Payments from drug & device makers

$5,582in general payments, 2019–2025

Across 158 payments — averaging $35.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Intuitive Surgical$744
  • Boston Scientific$587
  • Astellas Pharma US Inc$526
  • Johnson & Johnson$300
  • Medtronic$297
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$1,61529%
  • Food & beverage$3,69466%
  • Education$2735%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,582 in reported general payments places this provider in the 65th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$219,405
Medicare patients
530
Services billed
6,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide44$613,348
ErleadaApalutamide23$372,607
MyrbetriqMirabegron230$152,229
Estradiol176$21,258
GemtesaVibegron30$20,857
ElmironPentosan Polysulfate Sodium11$10,428
Potassium Citrate ErPotassium Citrate143$8,795
Tamsulosin Hcl733$8,086
OsphenaOspemifene20$7,205
Finasteride525$6,431
Fesoterodine Fumarate ErFesoterodine Fumarate59$5,819
Solifenacin Succinate177$5,700
Mirabegron ErMirabegron12$5,653
ToviazFesoterodine Fumarate11$5,322
Silodosin62$3,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$98$613,34844 claims
Johnson & JohnsonErleada$300$372,60723 claims
Astellas Pharma US IncMyrbetriq$526$152,229230 claims
Sumitomo Pharma America, Inc.Gemtesa$166$20,85730 claims
PfizerToviaz$58$5,32211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 225 urology providers in Colorado.

Other urology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →